Abstract
Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)
Current Pharmaceutical Design
Title: Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Volume: 9 Issue: 11
Author(s): O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat. M. Price and Eric O. Aboagye
Affiliation:
Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)
Abstract: Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Export Options
About this article
Cite this article as:
Hutchinson Clyde O., Collingridge R. David, Barthel Henryk, Price M. Pat. and Aboagye O. Eric, Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography, Current Pharmaceutical Design 2003; 9 (11) . https://dx.doi.org/10.2174/1381612033455251
DOI https://dx.doi.org/10.2174/1381612033455251 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Cerenkov Luminescence Imaging at a Glance
Current Molecular Imaging (Discontinued) Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design PET Imaging for Gene & Cell Therapy
Current Gene Therapy Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry The Role of Glioma Microenvironment in Immune Modulation: Potential Targets for Intervention
Letters in Drug Design & Discovery Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Determining the Relative Gene Expression Level of Hypoxia Related Genes in Different Cancer Cell Lines
Current Molecular Pharmacology Decorin Biology, Expression, Function and Therapy in the Cornea
Current Molecular Medicine The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Current Medicinal Chemistry EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Flavonoids: The Innocuous Agents Offering Protection against Alzheimer’s Disease Through Modulation of Proinflammatory and Apoptotic Pathways
Current Topics in Medicinal Chemistry